Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04244630 · ClinicalTrials.gov registry record · Phase 2
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
A Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Dallas VA Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04244630 is a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS) that is actively recruiting participants, run by Dallas VA Medical Center. The registered enrollment target is 60 participants, below the 258-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04244630, a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), is actively recruiting participants, sponsored by Dallas VA Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop the progression of ALS, for which currently no effective treatment exists. It is currently thought that oxidative stress is a major cause of ALS. The study investigators are therefore planning to expand the original scope of the previous trial by including anti-oxidants at high doses that were not previously used. All of these compounds are considered safe.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Antioxidants
Study Locations (1)
Texas
- VA North Texas Health Care System - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04244630
The ClinicalTrials.gov registry entry for NCT04244630 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 258-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (77% lower). The listed sponsor is Dallas VA Medical Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 1 intervention - of which Antioxidants is the first listed.
NCT04244630 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04244630 about?
NCT04244630 is a clinical study titled "Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial". The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple...
What is the current status of trial NCT04244630?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-11-02. Estimated completion is 2025-12.
What conditions does trial NCT04244630 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT04244630?
The interventions under investigation include: Antioxidants (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04244630?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04244630 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
COMPLETED · Phase 2
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.